Hair-loss treatments attract investor enthusiasm as next pharma boom

With no new approved drugs for pattern hair loss since the 1990s, companies like Veradermics and Absci have seen huge stock gains. Wall Street sees a lucrative market for out-of-pocket treatments, similar to the GLP-1 weight-loss drug surge. Cosmo's experimental treatment is closest to market, with analysts expecting significant sales.

EXPANDED:

The current standard treatments carry notable drawbacks. Minoxidil has been linked to heart palpitations, while finasteride can reduce libido, leaving many patients seeking alternatives. The market parallels the GLP-1 obesity drug surge, where consumer willingness to pay out-of-pocket created massive valuations for Eli Lilly and Novo Nordisk.

Cosmo's clascoterone targets the hormonal root cause of male-pattern baldness directly at the follicle, and the company plans to file with US regulators in early 2027. Veradermics is developing a tablet form of minoxidil, which could become the first approved pill for female-pattern hair loss. Absci's AI-designed injection is earlier stage